Long-term Efficacy and Tolerability of Adjunctive Aripiprazole for Major Depressive Disorder: Systematic Review and Meta-analysis
Clicks: 177
ID: 274324
2021
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
30.0
/100
151 views
24 readers
Trending
AI Quality Assessment
Not analyzed
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Given the scarcity of data, the authors of this review systematically synthesized the literature to determine the long-term efficacy and safety of aripiprazole as a maintenance augmenting agent for major depressive disorder. Read on to find out more.
| Reference Key |
seshadri2021thelong-term
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Ashok Seshadri;Michaela E. Wermers;Timothy J. Habermann;Balwinder Singh; |
| Journal | The primary care companion for CNS disorders |
| Year | 2021 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.